Skip to main content

Government Funding Lapse
Because of a lapse in government funding, the information on this website may not be up to date, transactions submitted via the website may not be processed, and the agency may not be able to respond to inquiries until appropriations are enacted.

The NIH Clinical Center (the research hospital of NIH) is open. For more details about its operating status, please visit cc.nih.gov.

Updates regarding government operating status and resumption of normal operations can be found at opm.gov.

TGF-beta2 antisense oligonucleotide TASO-001

A transforming growth factor (TGF)-beta2 specific antisense oligodeoxynucleotide (ASO), with potential antineoplastic activity. Upon administration, TGF-beta2 ASO TASO-001 binds to TGF-beta2 mRNA causing inhibition of protein translation. This decreases TGF-beta2 levels, which may result in the inhibition of tumor cell growth and migration, and tumor angiogenesis. TGF-beta2, a cytokine overexpressed in various malignancies, plays an important role in promoting the growth, progression, and migration of tumor cells.

Check for active clinical trials using this agent View this agent in the NCI Thesaurus

Synonym:	TGF-beta2 ASO TASO-001 TGF-beta2-targeting antisense oligonucleotide TASO-001
Code name:	TASO 001 TASO-001 TASO001

TGF-beta2 antisense oligonucleotide TASO-001

Search NCI's Drug Dictionary